ASCO 2017 | The serine biosynthesis pathway and its role in T-ALL

Kim Kampen • 22 Jun 2017

T-Cell Lymphoma

Kim Kampen, PhD, University of Leuven, Leuven, Belgium, discusses the implications of the ribosomal protein L10 (RPL10) R98S mutation, which occurs in 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, in the protein synthesis activity of cells. As detailed by Dr. Kampen, an upregulation in the serine biosynthesis pathway is observed in patients, which suggests that the mutation may be a reason as to why cells of patients with T-ALL show increased serine biosynthesis. As there are currently no inhibitors of serine biosynthesis available, this may be an interesting area of research. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.